期刊
JOURNAL OF INFECTIOUS DISEASES
卷 213, 期 10, 页码 1557-1561出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiw080
关键词
MERS-CoV; prophylaxis; m336; rabbits; human mAb
资金
- National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)
- National Cancer Institute, NIH
With >1600 documented human infections with Middle East respiratory syndrome coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical countermeasures are needed to prevent and limit the disease. We examined the in vivo efficacy of the human monoclonal antibody m336, which has high neutralizing activity against MERS-CoV in vitro. m336 was administered to rabbits intravenously or intranasally before infection with MERS-CoV. Prophylaxis with m336 resulted in a reduction of pulmonary viral RNA titers by 40-9000-fold, compared with an irrelevant control antibody with little to no inflammation or viral antigen detected. This protection in rabbits supports further clinical development of m336.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据